Annual Report 2012.pdf - Karo Bio

More documents

Recommendations

Info

acCounts Consolidated income statements and income statements for the Parent Company GROUP PARENT COMPANY KSEK Note 2012 2011 2010 2012 2011 Net sales 1 33,173 - - 33,173 - Operating expenses 2–5 Administrative expenses –25,116 –40,797 –32,869 –25,116 –40,797 R&D expenses –107,857 –189,321 –129,382 –108,207 –189,321 Other operating income and expenses 6 51 –1,041 412 51 –1,041 –132,922 –231,159 –161,839 –133,272 –231,159 Operating profit/loss –99,749 –231,159 –161,839 –100,099 –231,159 Income from financial investments Interest income and other similar income 7 1,510 5,921 802 1,510 5,921 Interest expenses and other similar expenses 8 –15 –1,388 –2,500 –3 –1,374 1,495 4,533 –1,698 1,507 4,547 Profit/loss after financial items –98,254 –226,626 –163,537 –98,592 –226,612 Tax 9 - - - - - PROFIT/LOSS FOR THE YEAR 10 –98,254 –226,626 –163,537 –98,592 –226,612 Earnings per share (SEK) 11 – based on weighted average number of shares outstanding –0.25 –0.59 –0.67 – based on weighted average number of shares fully diluted 1) –0.25 –0.59 –0.67 1) The last day for redemption for the warrants that were issued in the latest program was in April 2011. No dilutive effect from warrants outstanding is therefore taken into account. Consolidated statement of comprehensive income and comprehensive income for the Parent Company GROUP PARENT COMPANY KSEK Note 2012 2011 2010 2012 2011 Profit/loss for the period –98,254 –226,626 –163,537 –98,592 –226,612 Othet comprehensive income for the year, net of tax - - - - - TOTAL COMPREHENSIVE PROFIT/LOSS FOR THE PERIOD –98,254 –226,626 –163,537 –98,592 –226,612 Total comprehensive profit/loss attributable to: Shareholders of the parent company –98,254 –226,626 –163,537 –98,592 –226,612 18 KARO BIO Annual Report 2012
acCounts Consolidated statement of financial position and balance sheets for the Parent Company ASSETS (KSEK) GROUP PARENT COMPANY At December 31 Note 2012 2011 2010 2012 2011 NON-CURRENT ASSETS Intangible assets Licenses and similar rights 12 - - - - - Tangible assets Equipment 13, 20 3,771 5,558 4,585 3,509 5,412 Financial assets Participations in group companies 14 - - - 150 100 Total non-current assets 3,771 5,558 4,585 3,659 5,512 CURRENT ASSETS Current receivables Accounts receivable 6,371 - 101 6,371 - Other receivables 2,621 2,945 3,892 2,621 2,945 Prepaid expenses and accrued income 15 10,901 4,464 5,870 10,901 4,464 19,893 7,409 9,863 19,893 7,409 Financial assets at fair value through profit or loss 16, 28 26,049 114,780 69,548 26,049 114,780 Cash and cash equivalents 17 28,024 43,753 325,486 27,964 43,743 Total current assets 73,966 165,942 404,897 73,906 165,932 TOTAL ASSETS 77,737 171,500 409,482 77,565 171,444 KARO BIO Annual Report 2012 19
Page 1 and 2: Annual Report 2012
Page 3 and 4: About Karo Bio Karo Bio is a resear
Page 5 and 6: Vision, goal, business model and st
Page 7 and 8: CEO commentary Greater flexibility
Page 9 and 10: Project portfolio MK-6913 - collabo
Page 11 and 12: The share PRINCIPAL SHAREHOLDERS AT
Page 13 and 14: Five-year overview (SEK, unless oth
Page 15 and 16: Administration Report Between 2008
Page 17: Administration Report MSEK 1.1 of t
Page 21 and 22: acCounts Consolidated statement of
Page 23 and 24: Accounting and valuation principles
Page 29 and 30: NOTEs Executive management has also
Page 31 and 32: Notes NOTE 8 INTEREST EXPENSE AND O
Page 33 and 34: Notes NOTe 17 CASH AND CASH EQUIVAL
Page 35 and 36: Notes NOTE 26 REMUNERATION TO AUDIT
Page 37 and 38: Notes CURRENCY EFFECT (MSEK) Effect
Page 39 and 40: Auditor’s Report Auditor’s Repo
Page 41 and 42: Corporate Governance Report GENERAL
Page 43 and 44: Corporate Governance Report Executi
Page 45 and 46: Corporate Governance Report Board o
Page 47 and 48: Glossary Glossary AGONIST A compoun

Annual Report 2012.pdf - Karo Bio

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?